Odyssey Therapeutics, Inc. ODTX
At closeNov 11, 2026, 4:26 PM EST
After hours · Nov 11, 4:26 PM ET
- YTD
- +27.83%
- 1 year
- +27.83%
- Market cap
- 1.01B
- EPS (ttm)
- -6.33
- Shares out
- 48.07M
- Forward P/E
- -4.73
- YTD return
- +27.83%
- 1-year return
- +27.83%
- Volume
- 245.07K
- Avg volume
- 300.85K
- Open
- 19.98
- Previous close
- 20.00
- Day's range
- 19.22 – 21.21
- 52-week range
- 15.10 – 29.05
- Analysts
- Strong Buy
- Price target
- 34.67 (+65.2%)
- Earnings date
- Nov 4, 2026
5D -2.03 (-9.21%)
Key statistics
- Enterprise value
- 656.30M
- PEG ratio
- 0.00
- Price / book
- 2.68
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 326.00M
- Total debt
- 23.48M
- Return on equity
- 0.00%
- Short % of float
- 7.95%
- 50-day average
- 20.98
- 200-day average
- 19.71
Analyst view
Consensus: strong buy
- Target (low)
- 27.00
- Target (mean)
- 34.67
- Target (high)
- 42.00
- Strong buy2
- Buy6
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 4, 2026
Expected Nov 4, 2026. Consensus EPS estimate -1.03.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2026 | Sep 30, 2026 | -1.13 | — | — | — |
| Aug 4, 2026 | Jun 30, 2026 | -1.61 | -1.74 | -0.13 | -8.07% |
| Jun 17, 2026 | Mar 31, 2026 | -1.11 | -6.77 | -5.66 | -508.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 12, 2026 | UBS | init | — | Buy |
| Oct 9, 2026 | Raymond James | init | — | Outperform |
| Aug 27, 2026 | HC Wainwright & Co. | init | — | Buy |
| Aug 7, 2026 | JP Morgan | main | Overweight | Overweight |
| Jun 18, 2026 | Oppenheimer | reit | Outperform | Outperform |
| Jun 2, 2026 | Cantor Fitzgerald | init | — | Overweight |
About Odyssey Therapeutics, Inc.
Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of interferon regulatory factor 5 (IRF5); OD-003, a protein therapeutic designed to agonize tumor necrosis factor receptor 2 selectively on Treg; a TSLP/IL-33 bispecific antagonist; an oral small molecule interleukin-1 receptorassociated kinase 4 scaffolding inhibitor; and a small molecule inhibitor of IRF5. The company was incorporated in 2021 and is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- odysseytx.com
News
Odyssey Therapeutics Publishes Paper Titled 'TNFR2 agonism increases tissue and effector Treg cells In Journal Of Immunology 
HC Wainwright & Co. Assumes Odyssey Therapeutics at Buy, Announces Price Target of $40 
Odyssey Therapeutics Q3 EPS $(1.10) Misses $(1.08) Estimate 
Odyssey Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update 
UBS Initiates Coverage On Odyssey Therapeutics with Buy Rating, Announces Price Target of $27 
Odyssey Therapeutics To Present Design Of Randomized, Double-Blind Phase 2a Trial Evaluating OD-001 In Combination With Vedolizumab In Patients With UC At ACG 2026 Annual Scientific Meeting - Raymond James Initiates Coverage On Odyssey Therapeutics with Outperform Rating, Announces Price Target of $42
This Ascendis Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday 
HC Wainwright & Co. Initiates Coverage On Odyssey Therapeutics with Buy Rating, Announces Price Target of $44 
JP Morgan Maintains Overweight on Odyssey Therapeutics, Raises Price Target to $29
Your note
Sign in to keep a note on ODTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHU SHELLEY | Director | Purchase | May 10, 2026 | 11,111 |
| DIMENSION CAPITAL II, L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | May 7, 2026 | 0 |
| GLICK GARY D. PH.D. | Chief Executive Officer | Conversion of Exercise of derivative security | May 10, 2026 | 415,973 |
| HAAS JASON | Chief Financial Officer | Purchase | May 7, 2026 | 62,908 |
| LEIDEN JEFFREY M | Director | Conversion of Exercise of derivative security | May 10, 2026 | 0 |
| LI NAN LN | Director | Purchase | May 10, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 12.98% | 6,239,237 | 130.96M | Sep 29, 2026 |
| SR One Capital Management, LP | 7.89% | 3,794,883 | 79.65M | Jun 29, 2026 |
| TPG GP A, LLC | 7.68% | 3,690,146 | 77.46M | Jun 29, 2026 |
| Lightspeed Management Company, L.L.C. | 7.51% | 3,608,443 | 75.74M | Jun 29, 2026 |
| Orbimed Advisors LLC. | 6.24% | 3,001,198 | 63.00M | Jun 29, 2026 |
| Sanofi | 4.14% | 1,990,200 | 41.77M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 2.45% | 1,175,634 | 24.68M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.10% | 531,096 | 11.15M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 0.88% | 424,684 | 8.91M | Sep 29, 2026 |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 0.73% | 349,200 | 7.33M | Sep 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 0.68% | 329,062 | 6.91M | Sep 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Series Growth Company Fund | 0.59% | 284,000 | 5.96M | Sep 29, 2026 |